Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

New heart failure lead receives US FDA approval

Boston Scientific : 19 May, 2008  (New Product)
Boston Scientific has received US FDA approval of its Acuity Spiral left ventricular lead for use with cardiac resynchronization therapy defibrillators (CRT-D) and cardiac resynchronization therapy pacemakers (CRT-P), both of which treat heart failure.
The Acuity Spiral lead is the company's fifth generation left ventricular lead and second in the Acuity family of left ventricular leads.

The product features a spiral fixation design and small lead tip profile (4.1 French tapering to 2.6 French) for placement of the lead in veins of varying sizes, including difficult-to-access veins. A lead is an insulated wire that carries the heart signal to the implanted device and delivers energy from the device to the heart. In most cases, leads are passed into the heart through veins.

'In the US clinical trial, the Acuity Spiral fixation design provided excellent stability after implant,' said John Hummel, MD, principal investigator of the Acuity Spiral US clinical trial. 'Acuity Spiral has the smallest left ventricular lead tip profile in the industry, offering greater flexibility to place the lead in veins I may have avoided in the past.'

Boston Scientific is also conducting a prospective, multi-centre trial designed to collect and analyse real-world performance data for the Acuity Spiral lead. The study will enroll approximately 1,700 patients in up to 125 centres. Patients will be followed over a period of five years and will be enrolled on Boston Scientific's Latitude Patient Management system, enabling wireless remote management of patients.

'This study demonstrates Boston Scientific's commitment to quality and robust post-market surveillance of new leads,' said Arjun Sharma, MD, vice president, Patient Safety, Boston Scientific CRM. 'The data from this post- market study will provide us with a deeper understanding of the lead's performance in real-world practice and will be a welcome addition to the data we collected from the US clinical trial.'

Boston Scientific is the only company to offer four fixation designs that provide stability in a variety of venous anatomies, enabling physicians to select the most appropriate lead for their patients. The Acuity Spiral lead is designed for use with heart failure devices, such as the Cognis CRT-D, which has recently received FDA approval.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo